Ihre groesste Stärke entfalten Masken in Kombination mit weiteren Massnahmen. Ein gutes Bild dafür ist das Prinzip von Schweizer-Käse-Scheiben, das der australische Virologe Ian Mackay für das Coronavirus ersonnen hat. Die Löcher symbolisieren die Schlupflöcher für die Viren in den Schutzmass...nahmen – denn jede Massnahme für sich allein genommen wirkt nicht perfekt. Aber: Stehen die verschiedenen Käsescheiben hintereinander, so sitzen die Löcher jeweils an anderen Stellen. Dann passieren die heranflitzenden Viren vielleicht die erste und zweite Barriere, aber irgendwo weiter hinten in der Serie der Käsescheiben prallen sie dann doch auf Widerstand. Die Virologin Melanie Brinkmann hat dieses Käsescheiben-Modell sehr verständlich in diesem Video für Schüler erklärt
more
Measuring progress towards universal health coverage.
This sixth edition of Health at a Glance Asia/Pacific presents a set of key indicators of health status, the determinants of health, health care resources and utilisation, health care expenditure and financing and quality of care across 27 Asia-...Pacific countries and territories. It also provides a series of dashboards to compare performance across countries and territories, and a thematic analysis on the impact of the COVID-19 outbreak on Asia/Pacific health systems.
more
In this video we explore the MEDBOX Toolboxes, a special and very popular features of the online library MEDBOX.
To cover selected topics in more detail, MEDBOX collects the most relevant documents and information into Toolboxes. The topics range from various humanitarian crises such as natural ha...zards, refugees & migrants, through epidemics and pandemics such as Ebola and Covid-19 to major global health topics such as HIV, TB, mental health or global health education.
Videoclip Series "MEDBOX - The Aid Library" no.4
more
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir...respective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto...r vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks.
more
This free online course on Climate Change Negotiations and Health features key information on climate change and its impacts on human health, provides an overview of the international climate change negotiations so far, and considers entry points to address health issues and priorities within climat...e change negotiations and policies.
The course provides clear, concise, and up-to-date information for anybody interested in addressing the health risks arising from climate change. The course is self-paced and includes a series of self-standing interactive lessons with different activities, exercises, case studies and videos, as well as links to other useful resources. Upon successful completion of the course, participants can receive a certificate of completion.
more
Climate change is resulting in poorer health outcomes, increasing mortality and is a driver of health inequities. However, health is well placed to be a significant part of the solution; the positive health impacts from stronger climate change action can motivate stronger global ambition; health sys...tems which are resilient to climate change can help protect their populations from the negative impacts (in the short and longer terms); and sustainable low carbon health systems can make a substantial contribution to reducing national and global emissions.
This fact sheet on climate change and health is part of the Climate Fast Facts series of the United Nations Climate Action team.
more
The toolkit provides practical guidance and tools that can support efforts, including planning and implementation activities, to create dementia-inclusive societies.
The toolkit is divided into two parts. Part I contains background information and a conceptual framework for creating dementia-incl...usive societies. Part II includes four practical modules, each featuring a series of practical steps and exercises. The four modules focus on: starting a new dementia-friendly initiative (DFI), integrating dementia into an existing initiative, monitoring and evaluation a DFI, and scaling a DFI. The modules can be used together or separately and offer guidance that can be adapted to suit local needs and settings.
more
La presente publicación describe la literatura científica revisada sobre las intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019. El Ministerio de Salud solicitó la revisión de la evidencia disponible para nueve intervenciones terapéuticas frente a COVID-...19. Este listado contempla 03 intervenciones que no fueron consideradas en la Revisión Rápida de Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 . Serie Revisión Rápida N° 02-2020, correspondiendo a Ivermectina, Tocilizumab y pulsos de corticoides. En vista del rol potencial de cada intervención en el tratamiento de COVID-19, se plantearon dos respuestas PICO a fin de revisar la evidencia disponible respecto a siete potenciales opciones para tratamiento específico y dos fármacos que se han señalado como terapia adyuvante para frenar la respuesta inflamatoria presentada en COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19.
more
INTRODUCTION: Health service use among the public can decline during outbreaks and had been predicted among low and middle-income countries during the COVID-19 pandemic. In March 2020, the government of the Democratic Republic of the Congo (DRC) started implementing public health measures across Kin...shasa, including strict lock-down measures in the Gombe health zone.
METHODS: Using monthly time series data from the DRC Health Management Information System (January 2018 to December 2020) and interrupted time series with mixed effects segmented Poisson regression models, we evaluated the impact of the pandemic on the use of essential health services (outpatient visits, maternal health, vaccinations, visits for common infectious diseases and non-communicable diseases) during the first wave of the pandemic in Kinshasa. Analyses were stratified by age, sex, health facility and lockdown policy (i.e, Gombe vs other health zones).
RESULTS: Health service use dropped rapidly following the start of the pandemic and ranged from 16% for visits for hypertension to 39% for visits for diabetes. However, reductions were highly concentrated in Gombe (81% decline in outpatient visits) relative to other health zones. When the lock-down was lifted, total visits and visits for infectious diseases and non-communicable diseases increased approximately twofold. Hospitals were more affected than health centres. Overall, the use of maternal health services and vaccinations was not significantly affected.
CONCLUSION: The COVID-19 pandemic resulted in important reductions in health service utilizsation in Kinshasa, particularly Gombe. Lifting of lock-down led to a rebound in the level of health service use but it remained lower than pre-pandemic levels.
more
The humanitarian-development-peace nexus (HDPNX) is a new way of working that offers a framework for coherent joined-up planning and implementation of shared priorities between humanitarian development and peacebuilding actors in emergency settings. To advance the HDPNx in a given country a sh...ared foundational understanding of the current situation is needed. However it can be challenging to find such a resource perpetuating poor understanding planning and operationalization. This is one of a series of country profiles that have been developed by WHO to address that need. Each profile provides an overview of health-related nexus efforts in the country and will be updated regularly.
more
This set of competencies reflects foundational climate and health knowledge, skills, abilities, and attitudes for health professions students to mitigate the health impacts of climate change. Intended as a guide for developing climate and health education in health professions schools’ curricula, ...the set can be applied as needed and included in a variety of formats and over different timescales, such as in slides over several years of teaching, a series of lectures, or an entire course. The set of competencies offers an overview 2 of the different domains, units, and elements of competency recommended for all health professions students, as well as specific competencies for public health and clinical practices.
more
El Ministerio de Salud de Chile, atendida la relevancia de los medicamentos dentro del sistema de salud público y privado, ha planteado en la Política Nacional de Medicamentos (Res. Ex. MINSAL Nº 512/2004) los lineamientos y directrices bajo las cuales se deberá desarrollar la actividad nacional... en materia farmacéutica y dentro de éstos de encuentran las líneas de acción respecto de la Racionalidad en el Uso
de Medicamentos, que estructuran una serie de actividades destinadas a lograr un uso racional de los mismos.
more
March 2021
This report presents the key findings of the NFHS-5 survey in the National Capital Territory (NCT) of Delhi, followed by detailed tables and an appendix on sampling errors. The 2019-21 National Family Health Survey (NFHS-5), the fifth in the NFHS series, provides information on populatio...n, health, and nutrition for India and each state and union territory.
more
The development of this Operational Roadmap has been driven by a growing consensus in Ukraine on the need to prioritize activities that are urgently required to address the mental health and psychosocial needs of the country’s population and also the importance of basing the response on existing s...tructures, resources and innovations introduced in reforms in past years.
According to this consensus, new resources mobilized by and for Ukraine should complement existing ones, in line with the national vision and with best international standards, and should be planned in a way that further strengthens the country’s mental health system.
The Government of Ukraine is committed to urgently addressing the mental health and psychosocial needs of the population, under the auspices of the First Lady of Ukraine and the leadership of the recently established Intersectoral Coordination Council for Mental Health and Psychological Assistance to Victims of the Armed Aggression of the Russian Federation against Ukraine (referred to in this document as the Intersectoral Coordination Council).
This Roadmap has been developed following a series of consultations with Ukrainian authorities and national and international agencies working in the area of mental health and psychosocial support (MHPSS) and engaged in emergency response in Ukraine. The consultation process was organized by the Ministry of Health of Ukraine (MOH) and supported by WHO Ukraine, under the auspices of the First Lady of Ukraine and in collaboration with the MHPSS Technical Working Group of Ukraine (MHPSS TWG Ukraine) and the IASC MHPSS Reference Group (IASC MHPSS RG), and building on substantial advances in the mental health sector under existing programmes in the country.
The Roadmap is informed by international technical guidance and national policies and plans, including the IASC Guidelines on MHPSS in Emergency Settings, the Minimum Services Package for MHPSS in Emergencies (MHPSS MSP), the IASC Common Monitoring and Evaluation Framework, the World Health Organization (WHO)’s Comprehensive Mental Health Action Plan 2013– 2030, the WHO European Framework for Action on Mental Health, the Concept for Development of Mental Health Care in Ukraine until 2030, the National Mental Health Action Plan for 2021–2023 and the National Recovery and Development Plan.
Informed by the overall goal of MHPSS assistance in Ukraine – to reduce suffering and improve the mental health and psychosocial well-being of the affected population – the Roadmap aims to provide a consolidated overview of envisioned MHPSS priorities, informed by the local context and the vision of the Government of Ukraine together with national and international partners, and with the best available evidence and resources, to all MHPSS stakeholders already engaged in or joining emergency response and recovery efforts in Ukraine.
As well as information on the context in Ukraine, the Roadmap includes:
• a list of evidence-based MHPSS interventions and services contextualized and introduced in Ukraine in recent years (described in Table 1) and
• a set of multisectoral actions to scale up MHPSS services in both the short and longer terms, informed by available evidence, international technical guidance and expert consensus (described in Table 2).
more
El presente documento reúne un conjunto de recomendaciones formuladas por la Organización Mundial de la Salud (OMS) y la Organización Panamericana de la Salud (OPS) para ayudar, a los profesionales encargados de los programas de control de vectores de Latinoamérica y el Caribe a nivel nacional, ...subnacional y local, a actualizar y tomar decisiones basadas en la evidencia sobre las medidas de control más apropiadas para cada situación específica. El MIV puede utilizarse cuando la meta es la vigilancia y el control o la eliminación (dependiendo de la situación específica) de las ETV y puede contribuir a reducir el desarrollo de la Resistencia a los insecticidas mediante el uso racional de estos productos. Este documento contiene las instrucciones para llevar a cabo el mandato de la OPS del 2008 sobre el control integrado de vectores (resolución CD48.R8, documento CD48/13) y, en particular, complementa una serie de guías de la OMS publicadas en el 2012
more
Este documento reúne um conjunto de recomendações formuladas pela OMS e pela OPAS para ajudar os profissionais responsáveis pelos programas de controle de vetores nas Américas em nível nacional, subnacional e local a se atualizarem e tomarem decisões baseadas em evidências sobre as medidas d...e controle mais apropriadas para cada situação. O MIV pode ser utilizado quando o objetivo é a vigilância e o controle ou a eliminação (dependendo da situação específica) das DTVs e pode ajudar a reduzir o desenvolvimento de resistência aos inseticidas pelo uso racional desses produtos. Este documento contém instruções para a execução do mandato de 2008 da OPAS sobre o manejo integrado de vetores (resolução CD48.R8, documento CD48/13) e, em particular, complementa uma série de diretrizes da OMS publicadas em 2012
more
After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge...s of the clinical trials of fexinidazole. The screening of the Drugs for Neglected Diseases initiative (DNDi) HAT-library by the Swiss TPH had singled out fexinidazole, originally developed by Hoechst (now Sanofi), as the most promising of a series of over 800 nitroimidazoles and related molecules. In cell culture, fexinidazole has an IC50 of around 1 µM against Trypanosoma brucei and is more than 100-fold less toxic to mammalian cells. In the mouse model, fexinidazole cures both the first, haemolymphatic, and the second, meningoencephalitic stage of the infection, the latter at 100 mg/kg twice daily for 5 days. In patients, the clinical trials managed by DNDi and supported by Swiss TPH mainly conducted in the Democratic Republic of the Congo demonstrated that oral fexinidazole is safe and effective for use against first- and early second-stage sleeping sickness. Based on the positive opinion issued by the European Medicines Agency in 2018, the WHO has released new interim guidelines for the treatment of HAT including fexinidazole as the new therapy for first-stage and non-severe second-stage sleeping sickness caused by Trypanosoma brucei gambiense (gHAT). This greatly facilitates the diagnosis and treatment algorithm for gHAT, increasing the attainable coverage and paving the way towards the envisaged goal of zero transmission by 2030.
more
The twentieth century ended with human African trypanosomiasis (HAT) epidemics raging across many parts of Africa. Resistance to existing drugs was emerging, and many programs aiming to contain the disease had ground to a halt, given previous success against HAT and the competing priorities associat...ed with other medical crises ravaging the continent. A series of dedicated interventions and the introduction of innovative routes to develop drugs, involving Product Development Partnerships, has led to a dramatic turnaround in the fight against HAT caused by Trypanosoma brucei gambiense. The World Health Organization have been able to optimize the use of existing tools to monitor and intervene in the disease. A promising new oral medication for stage 1 HAT, pafuramidine maleate, ultimately failed due to unforeseen toxicity issues. However, the clinical trials for this compound demonstrated the possibility of conducting such trials in the resource-poor settings of rural Africa.
more
The WHO continuously reviews available data on SARS-CoV-2 variants of concern. For this version, the global epidemiological
situation of the COVID-19 pandemic as of 21 January 2022 – at a time when the Omicron VOC had been identified in 171
countries across all six WHO Regions and was rapidly re...placing Delta worldwide – was considered Omicron has a substantial growth advantage, higher secondary attack rates and a higher observed reproduction number than Delta.
There is now significant evidence that immune evasion contributes to the rapid spread of Omicron. Other factors may be a shorter
serial interval (by about 0.8 to 1.2 days compared to Delta) and potential increased intrinsic transmission fitness . There is
growing evidence that with Omicron, there is lower vaccine effectiveness (VE) against infection and symptomatic disease soon after vaccination compared to Delta. There is also evidence of accelerated waning of VE over time of the primary series against infection and symptomatic disease for the studied vaccines. Further studies are required to better understand the drivers of transmission and declining incidence in various settings. These factors include the intrinsic transmission fitness properties of the virus, degree of immune evasion, vaccination coverage and level of vaccine-derived and post-infection immunity, levels of social mixing and degree of application of public health and social measures (PHSM).
more